longer subject to Section 16. Form 4 or

Form 5 obligations may continue. *See* Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

OMB APPROVAL OMB 3235-Number: 0287 Estimated average burden hours per response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(1 Thit of Type Responses)										
1. Name and Address of Reporting WEIS KONRAD M PHD	2. Issuer Name and Ticker or Trading Symbol TITAN PHARMACEUTICALS INC [TTP] 3. Date of Earliest Transaction					IC	5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)  _X_Director			
C/O TITAN PHARMACEUT INC, 400 OYSTER POINT E SUITE 505	(Month/Day/	(Month/Day/Year) 03/10/2006								
(Street) S SAN FRANCISCO, CA 940	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	Table I - I	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
(Instr. 3) Date Exec (Month/Day/Year) any		Deemed ecution Date, if onth/Day/Year)	3. Transaction Code (Instr. 8)		Disposed of (D) (Instr. 3, 4 and 5)		D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)	(I) (Instr. 4)	(11001 1)
Common Stock 03/10/2006	6		M		13,125	A	\$ 1.71	48,699	D	
Common Stock 03/10/2006	6		M		5,000	A	\$ 1.71	53,699	D	
Common Stock 03/10/2006	6		M		5,000	A	\$ 1.71	58,699	D	
Reminder: Report on a separate line directly or indirectly.	e for each o	class of securitie	s benefic	ially	owned					
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.									

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Der Sec	eurity str. 3)	Conversion	Date (Month/Day/Year)	4. Transac Code (Instr. 8	tion	on of Derivative		Expiration Date		Securities		8. Price of Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial
				Code	V	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
to Pu	rchase mmon ock	\$ 1.71	03/10/2006	M			13,125	(1)	08/16/2012	Common Stock	13,125	\$ 1.71	0	D	
to Pu	rchase mmon ock	\$ 1.71	03/10/2006	M			5,000	(2)	08/16/2012	Common Stock	5,000	\$ 1.71	0	D	
to Pu	rchase mmon ock	\$ 1.71	03/10/2006	M			5,000	(2)	08/16/2012	Common Stock	5,000	\$ 1.71	0	D	

### **Reporting Owners**

Denouting Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
WEIS KONRAD M PHD C/O TITAN PHARMACEUTICALS INC 400 OYSTER POINT BLVD, SUITE 505 S SAN FRANCISCO, CA 94080	ı x						

### **Signatures**

/s/ Konrad M. Weiss	03/13/2006
Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- $\textbf{(1)}\ \ Vested\ in\ 48\ equal\ monthly\ installments\ from\ date\ of\ grant.\ The\ shares\ were\ fully\ vested\ on\ August\ 16,\ 2006.$
- $\textbf{(2)} \ \ Vested in 12 \ equal monthly installments from date of grant. The shares were fully vested on August 16, 2003.$

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.